Pharmaceutical Executive

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

Today's episode covers the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufacturers, and a White House plan to restrict treatments discovered in China.

Big changes are on the horizon for the pharmaceutical industry as Lundbeck and Novo Nordisk announce significant layoffs, impacting over 9,000 employees worldwide. The tumult highlights financial pressures within the sector. Meanwhile, former President Trump stirs the pot by criticizing direct-to-consumer drug advertising, sparking a heated debate about pharmaceutical pricing and marketing practices. This discussion sheds light on the complexities of drug promotion and its consequences for consumers.

In today’s Pharmaceutical Executive Daily, we explore strategies to strengthen pharma sales messaging, the role of AI-driven simulations in field rep training, and the FDA’s updated Green List restricting ingredients used in GLP-1 compounding.